Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-19 15:45 | 2025-11-17 | CRVO | CervoMed Inc. | Gregoire Sylvie | Director, 10% owner | BUY | $8.46 | 21,600 | $182,736 | 12,500 |
| 2025-11-19 15:45 | 2025-11-17 | CRVO | CervoMed Inc. | ELDER WILLIAM ROBERT | Officer | BUY | $8.36 | 3,500 | $29,250 | 12,500 |
| 2025-11-19 15:45 | 2025-11-17 | CRVO | CervoMed Inc. | ALAM JOHN J | Director, Officer, 10% owner | BUY | $8.46 | 21,600 | $182,736 | 12,500 |
| 2025-11-20 00:05 | 2025-11-17 | CYPH | CYPHERPUNK TECHNOLOGIES INC. | CAVANAUGH JAMES H | Director | SELL | $3.14 | 261,840 | $822,178 | 0 |
| 2025-11-19 00:00 | 2025-11-17 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $1,030.68 | 9,886 | $10,189,270 | 92,872,191 |
| 2025-11-19 00:24 | 2025-11-17 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Officer | SELL | $25.19 | 8,500 | $214,090 | 401,142 |
| 2025-11-19 00:01 | 2025-11-14 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine | Officer | SELL | $25.11 | 30,000 | $753,321 | 28,384 |
| 2025-11-18 15:29 | 2025-11-17 | BHVN | Biohaven Ltd. | Clark George C. | Officer | BUY | $8.52 | 17,000 | $144,770 | 20,000 |
| 2025-11-19 00:18 | 2025-11-17 | CNTA | Centessa Pharmaceuticals plc | HUSSAIN IQBAL J | Officer | OPT+S | $27.64 | 6,000 | $165,835 | 105,386 |
| 2025-11-19 00:17 | 2025-11-17 | CNTA | Centessa Pharmaceuticals plc | Bush Tia L | Officer | OPT+S | $28.00 | 40,000 | $1,120,000 | 121,503 |
| 2025-11-19 02:59 | 2025-11-17 | DAWN | Day One Biopharmaceuticals, Inc. | Bender Jeremy | Director, Officer | OPT+S | $8.91 | 15,894 | $141,690 | 177,165 |
| 2025-11-19 03:00 | 2025-11-17 | DAWN | Day One Biopharmaceuticals, Inc. | Merendino Lauren | Officer | OPT+S | $8.91 | 3,726 | $33,216 | 50,809 |
| 2025-11-19 03:04 | 2025-11-17 | DAWN | Day One Biopharmaceuticals, Inc. | Dubow Adam | Officer | OPT+S | $8.91 | 4,319 | $38,503 | 62,626 |
| 2025-11-19 03:28 | 2025-11-17 | BBIO | BridgeBio Pharma, Inc. | Trimarchi Thomas | Officer | SELL | $66.46 | 16,934 | $1,125,405 | 382,830 |
| 2025-11-19 02:39 | 2025-11-14 | NATR | NATURES SUNSHINE PRODUCTS INC | Brower Nathan G | Officer | SELL | $20.81 | 3,800 | $79,078 | 46,735 |
| 2025-11-19 00:27 | 2025-11-17 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | Director, Officer | SELL | $25.20 | 10,916 | $275,047 | 35,978 |
| 2025-11-19 00:36 | 2025-11-14 | TRDA | Entrada Therapeutics, Inc. | PARMAR KUSH | Director, 10% owner | SELL | $8.80 | 200,000 | $1,760,000 | 2,963,066 |
| 2025-11-19 03:02 | 2025-11-17 | DAWN | Day One Biopharmaceuticals, Inc. | York Charles N II | Officer | OPT+S | $8.91 | 4,062 | $36,212 | 294,715 |
| 2025-11-19 00:22 | 2025-11-14 | STOK | Stoke Therapeutics, Inc. | Krainer Adrian R. | Director | SELL | $26.98 | 40,472 | $1,092,060 | 364,246 |
| 2025-11-19 00:30 | 2025-11-15 | MCRB | Seres Therapeutics, Inc. | Young Teresa L. | Officer | OPT+S | $17.30 | 1,042 | $18,027 | 8,401 |
| 2025-11-19 00:30 | 2025-11-15 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | Director | OPT+S | $17.30 | 217 | $3,754 | 11,113 |
| 2025-11-19 00:30 | 2025-11-15 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R | Officer | OPT+S | $17.30 | 1,257 | $21,746 | 7,527 |
| 2025-11-18 18:05 | 2025-11-17 | APLS | Apellis Pharmaceuticals Inc. | Watson David O. | Officer | SELL | $20.06 | 5,000 | $100,300 | 108,730 |
| 2025-11-19 00:15 | 2025-11-18 | BIXT | BIOXYTRAN, INC | Hoberman Alan M | Director | BUY | $0.60 | 210,000 | $126,000 | 210,000 |
| 2025-11-19 00:30 | 2025-11-15 | MCRB | Seres Therapeutics, Inc. | DesRosier Thomas | Officer | OPT+S | $17.30 | 76 | $1,315 | 7,623 |
| 2025-11-19 01:30 | 2025-11-14 | RNTX | Rein Therapeutics, Inc. | Voss Capital, LP | 10% owner | BUY | $1.22 | 104,183 | $127,593 | 926,441 |
| 2025-11-19 05:45 | 2025-11-14 | CRMD | CorMedix Inc. | Dillione Janet | Director | SELL | $11.42 | 30,000 | $342,600 | 48,473 |
| 2025-11-19 01:18 | 2025-11-18 | OPK | OPKO HEALTH, INC. | FROST PHILLIP MD ET AL | Director, Officer, 10% owner | BUY | $1.27 | 533,300 | $678,891 | 214,966,448 |
| 2025-11-18 15:44 | 2025-11-14 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Director | BUY | $2.11 | 15,000 | $31,650 | 2,470,539 |
| 2025-11-19 00:34 | 2025-11-14 | TRDA | Entrada Therapeutics, Inc. | 5AM Ventures V, L.P. | 10% owner | SELL | $8.80 | 200,000 | $1,760,000 | 2,963,066 |
| 2025-11-19 00:20 | 2025-11-14 | INSM | INSMED Inc | ANDERSON ELIZABETH M | Director | SELL | $195.87 | 10,000 | $1,958,700 | 63,729 |
| 2025-11-19 00:21 | 2025-11-17 | INSM | INSMED Inc | LEE LEO | Director | SELL | $195.90 | 75,000 | $14,692,253 | 54,677 |
| 2025-11-19 00:36 | 2025-11-17 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $470.43 | 22,500 | $10,584,756 | 0 |
| 2025-11-19 00:35 | 2025-11-17 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $470.36 | 21,000 | $9,877,535 | 8,118 |
| 2025-11-19 00:35 | 2025-11-14 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $465.25 | 8,000 | $3,721,966 | 130 |
| 2025-11-19 03:50 | 2025-11-17 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $44.19 | 10,560 | $466,631 | 49,680 |
| 2025-11-19 00:23 | 2025-11-18 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $66.45 | 2,200 | $146,190 | 140,610 |
| 2025-11-19 00:26 | 2025-11-18 | RMTI | ROCKWELL MEDICAL, INC. | COOPER JOHN G | Director | SELL | $0.87 | 5,079 | $4,419 | 140,372 |
| 2025-11-18 00:00 | 2025-11-14 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $425,738.48 | 178,295 | $75,907,041,792 | 92,882,077 |
| 2025-11-18 05:23 | 2025-11-17 | TTRX | Turn Therapeutics Inc. | Chaudhary Zuraiz | Officer | BUY | $3.62 | 2,500 | $9,050 | 7,550 |
| 2025-11-18 03:03 | 2025-11-13 | TYRA | Tyra Biosciences, Inc. | Bensen Daniel | Officer | SELL | $16.04 | 131,411 | $2,108,069 | 296,570 |
| 2025-11-18 00:42 | 2025-11-13 | FGEN | KYNTRA BIO, INC. | Wettig Thane | Director, Officer | BUY | $9.12 | 3,700 | $33,750 | 24,939 |
| 2025-11-18 03:56 | 2025-11-13 | ARQT | Arcutis Biotherapeutics Inc. | Krishnamohan Neha | Director | OPT+S | $23.20 | 40,504 | $939,494 | 22,123 |
| 2025-11-17 15:30 | 2025-11-13 | BHVN | Biohaven Ltd. | Coric Vlad | Director, Officer | BUY | $7.50 | 666,666 | $4,999,995 | 740,546 |
| 2025-11-18 01:52 | 2025-11-13 | ROIV | Roivant Sciences Ltd. | Ramaswamy Vivek | 10% owner | SELL | $20.46 | 1,854,603 | $37,939,057 | 33,653,756 |
| 2025-11-18 03:22 | 2025-11-13 | HOWL | Werewolf Therapeutics, Inc. | MPM BioVentures 2014, L.P. | 10% owner | SELL | $0.96 | 209,652 | $200,658 | 5,481,539 |
| 2025-11-18 01:58 | 2025-11-13 | XERS | Xeris Biopharma Holdings, Inc. | Shannon John Patrick Jr | Director, Officer | OPT+S | $7.46 | 23,242 | $173,402 | 2,643,153 |
| 2025-11-18 00:05 | 2025-11-14 | AVTX | Avalo Therapeutics, Inc. | Goldman Jonathan | Director | OPT+S | $14.33 | 11,367 | $162,937 | 0 |
| 2025-11-18 00:48 | 2025-11-13 | MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | Brust Bernd | Director, Officer | BUY | $3.25 | 216,212 | $702,689 | 466,771 |
| 2025-11-17 16:01 | 2025-11-13 | CATX | Perspective Therapeutics, Inc. | Hunt Jonathan Robert | Officer | BUY | $2.03 | 11,000 | $22,295 | 59,800 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.